Home News Vaccine maker Valneva’s shares slump after UK ends COVID-19 deal
Our website publishes news, press releases, opinion and advertorials on various financial organizations, products and services which are commissioned from various Companies, Organizations, PR agencies, Bloggers etc. These commissioned articles are commercial in nature. This is not to be considered as financial advice and should be considered only for information purposes. It does not reflect the views or opinion of our website and is not to be considered an endorsement or a recommendation. We cannot guarantee the accuracy or applicability of any information provided with respect to your individual or personal circumstances. Please seek Professional advice from a qualified professional before making any financial decisions. We link to various third-party websites, affiliate sales networks, and to our advertising partners websites. When you view or click on certain links available on our articles, our partners may compensate us for displaying the content to you or make a purchase or fill a form. This will not incur any additional charges to you. To make things simpler for you to identity or distinguish advertised or sponsored articles or links, you may consider all articles or links hosted on our site as a commercial article placement. We will not be responsible for any loss you may suffer as a result of any omission or inaccuracy on the website.

Vaccine maker Valneva’s shares slump after UK ends COVID-19 deal

by maria gbaf

PARIS (Reuters) -Valneva shares plunged around 40% in early Monday trading after the British government ended a COVID-19 vaccine supply deal with the French company, alleging a breach of obligations that Valneva denies.

The company’s COVID-19 vaccine candidate VLA 2001 relies on inactivated virus, similar to flu vaccines, and is seen by some as having the potential to win over people who are wary of some current vaccines using new mRNA technology.

The British government “has alleged that the company is in breach of its obligations under the supply agreement, but the company strenuously denies this,” Valneva said in a statement, without giving further details.

“Valneva has worked tirelessly, and to its best efforts, on the collaboration … including investing significant resources and effort,” it added.

The British government had no immediate comment.

Despite Monday’s steep fall, Valneva’s shares are still up by around 50% since the start of 2021.

The company said it was still continuing its development plan for VLA 2001.

“Valneva believes that initial approval for VLA2001 could be granted in late 2021”, the company added.

(Reporting by Sudip Kar-Gupta and Benoit Van Overstraeten; Editing by Ana Nicolaci da Costa and Mark Potter)

You may also like